# EDGAR Filing Document

**Accession Number:** 0001847367
**File Stem:** 0000905148-25-004092
**Filing Date:** 2025-11
**Character Count:** 17106
**Document Hash:** c2fda9ded3a597710cf0b147ded74784
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000905148-25-004092.hdr.sgml**: 20251117

**ACCESSION NUMBER**: 0000905148-25-004092

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13G/A

**PUBLIC DOCUMENT COUNT**: 3

**FILED AS OF DATE**: 20251117

**DATE AS OF CHANGE**: 20251117

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ALUMIS INC.
- **CENTRAL INDEX KEY:** 0001847367
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-94550
- **FILM NUMBER:** 251490338

**BUSINESS ADDRESS:**
- **STREET 1:** 280 EAST GRAND AVENUE
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** 650-231-6625

**MAIL ADDRESS:**
- **STREET 1:** 280 EAST GRAND AVENUE
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ESKER THERAPEUTICS, INC.
- **DATE OF NAME CHANGE:** 20230427

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** FL2021-001, Inc.
- **DATE OF NAME CHANGE:** 20210222
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** venBio Global Strategic Fund IV, L.P.
- **CENTRAL INDEX KEY:** 0001862109

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G/A

**BUSINESS ADDRESS:**
- **STREET 1:** 1700 OWENS STREET, SUITE 595
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94158
- **BUSINESS PHONE:** 415-522-0100

**MAIL ADDRESS:**
- **STREET 1:** 1700 OWENS STREET, SUITE 595
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94158

## Ex-1

#### EXHIBIT 1

#### JOINT FILING AGREEMENT

The undersigned hereby agree that the statement on Schedule 13G with respect to the Common Stock of Alumis Inc. dated as of November 17, 2025 is, and any amendments thereto (including amendments on Schedule 13D) signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.

---

| | | |
|:---|:---|:---|
| Dated: November 17, 2025 |  |  |
|  | VENBIO GLOBAL STRATEGIC FUND IV, L.P. | VENBIO GLOBAL STRATEGIC FUND IV, L.P. |
|  | By: | VENBIO GLOBAL STRATEGIC GP IV, LLC<br> General Partner |
|  | By: | \* |
|  | Title: | Member |
|  | By: | \* |
|  | Title: | Member |
|  | VENBIO GLOBAL STRATEGIC GP IV, LLC | VENBIO GLOBAL STRATEGIC GP IV, LLC |
|  | By: | \* |
|  | Title: | Member |
|  | By: | \* |
|  | Title: | Member |
|  |  | \* |
|  |  | Corey Goodman |
|  |  | \* |
|  |  | Robert Adelman |
|  | \*By: | /s/ David Pezeshki |
|  | Title: | David Pezeshki<br> As attorney-in-fact |

---

This Agreement was executed by David Pezeshki on behalf of the individual listed above pursuant to a Power of Attorney, a copy of which is attached as Exhibit 2.

## Ex-2

#### EXHIBIT 2

#### POWER OF ATTORNEY

KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints David Pezeshki his true and lawful attorney-in-fact, with full power of substitution, to sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be executed on behalf of himself as an individual or in his capacity as a direct or indirect general partner, director, officer, member or manager of any partnership, corporation or limited liability company, pursuant to section 13 or 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and any and all regulations promulgated thereunder, and to file the same, with all exhibits thereto, and any other documents in connection therewith, with the Securities and Exchange Commission, and with any other entity when and if such is mandated by the Exchange Act or by the Financial Industry Regulatory Authority, granting unto said attorney-in-fact full power and authority to do and perform each and every act and thing necessary, desirable or appropriate, fully to all intents and purposes as he might or could do in person, thereby ratifying and confirming all that said attorney-in-fact, or his substitutes, may lawfully do or cause to be done by virtue hereof.

IN WITNESS WHEREOF, this Power of Attorney has been signed as of the 10th day of February, 2017.

---

| |
|:---|
| /s/ Robert Adelman |
| Robert Adelman |
| /s/ Corey Goodman |
| Corey Goodman |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13G

### Under the Securities Exchange Act of 1934

**(Amendment No. 1)**

**Issuer:** ALUMIS INC.

**Title of Class of Securities:** Common Stock, $0.0001 par value per share

**CUSIP Number:** 022307102

**Date of Event Which Requires Filing of this Statement:** 06/30/2025

**Check the appropriate box to designate the rule pursuant to which this Schedule is filed:**

- [ ] Rule 13d-1(b)

- [x] Rule 13d-1(c)

- [ ] Rule 13d-1(d)

---

| 1. | Names of Reporting Persons<br>venBio Global Strategic Fund IV, L.P. | Names of Reporting Persons<br>venBio Global Strategic Fund IV, L.P. |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>DE | Citizenship or Place of Organization<br>DE |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>4619803 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>4619803 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>4619803 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>4619803 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>4.8% | Percent of Class Represented by Amount in Row (9)<br>4.8% |
| 12. | Type of Reporting Person (See Instructions)<br>PN | Type of Reporting Person (See Instructions)<br>PN |

---

| 1. | Names of Reporting Persons<br>venBio Global Strategic GP IV, LLC | Names of Reporting Persons<br>venBio Global Strategic GP IV, LLC |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>DE | Citizenship or Place of Organization<br>DE |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>4619803 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>4619803 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>4619803 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>4619803 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>4.8% | Percent of Class Represented by Amount in Row (9)<br>4.8% |
| 12. | Type of Reporting Person (See Instructions)<br>OO, HC | Type of Reporting Person (See Instructions)<br>OO, HC |

---

| 1. | Names of Reporting Persons<br>Adelman Robert J | Names of Reporting Persons<br>Adelman Robert J |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>X1 | Citizenship or Place of Organization<br>X1 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>4619803 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>4619803 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>4619803 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>4619803 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>4.8% | Percent of Class Represented by Amount in Row (9)<br>4.8% |
| 12. | Type of Reporting Person (See Instructions)<br>IN, HC | Type of Reporting Person (See Instructions)<br>IN, HC |

---

| 1. | Names of Reporting Persons<br>GOODMAN COREY S | Names of Reporting Persons<br>GOODMAN COREY S |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>X1 | Citizenship or Place of Organization<br>X1 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>4619803 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>4619803 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>4619803 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>4619803 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>4.8% | Percent of Class Represented by Amount in Row (9)<br>4.8% |
| 12. | Type of Reporting Person (See Instructions)<br>IN, HC | Type of Reporting Person (See Instructions)<br>IN, HC |

---

**Item 1(a). Name of Issuer:**
ALUMIS INC.

**Item 1(b). Address of Issuer's Principal Executive Offices:**
280 East Grand Avenue, South San Francisco, California, 94080

**Item 2(a). Name of Person Filing:**
This Statement is filed on behalf of the following persons (collectively, the "Reporting Persons"):

i. venBio Global Strategic Fund IV, L.P. ("Fund IV");
ii. venBio Global Strategic GP IV, LLC ("General Partner IV");
iii. Robert Adelman ("Mr. Adelman"); and
iv. Corey Goodman ("Mr. Goodman").

This Statement relates to shares of Common Stock, $0.0001 par value per share ("Shares") directly beneficially owned by Fund IV. General Partner IV is the sole general partner of Fund IV. Mr. Adelman and Mr. Goodman are members of General Partner IV. Accordingly, each of General Partner IV, Mr. Adelman and Mr. Goodman may be deemed to indirectly beneficially own the Shares reported herein. Each Reporting Person disclaims beneficial ownership of such securities except for the Shares, if any, such Reporting Person holds of record.

**Item 2(b). Address of Principal Business Office:**
The address of the principal business office of each Reporting Person is c/o venBio Partners, LLC, 1700 Owens Street, Suite 595, San Francisco, CA 94158.

**Item 2(c). Citizenship:**
Fund IV is a Delaware limited partnership. General Partner IV is a Delaware limited liability company. Each of Mr. Adelman and Mr. Goodman is a citizen of the United States of America.

**Item 2(d). Title of Class of Securities:**
Common Stock, $0.0001 par value per share

**Item 2(e). CUSIP Number:**
022307102

**Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

(a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

(b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

(c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

(d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

(e) [ ] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f) [ ] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g) [ ] A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) [ ] A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), if filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

(k) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

**Item 4. Ownership:**

**(a) Amount beneficially owned:**

As of June 30, 2025, each of the Reporting Persons may be deemed to beneficially own 4,619,803 Shares.

**(b) Percent of class:**

The percentages set forth in row 11 are based on 96,857,569 Shares outstanding as of June 30, 2025, as reported in the Issuer's quarterly report on Form 10-Q filed with the Securities and Exchange Commission on August 13, 2025.

**(c) Number of shares as to which the person has:**

**(i) Sole power to vote or to direct the vote:**

See Line 5 of cover sheets.

**(ii) Shared power to vote or to direct the vote:**

See Line 6 of cover sheets.

**(iii) Sole power to dispose or to direct the disposition of:**

See Line 7 of cover sheets.

**(iv) Shared power to dispose or to direct the disposition of:**

See Line 8 of cover sheets.

**Item 5. Ownership of Five Percent or Less of a Class.**

[ ] If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.

**Item 6. Ownership of More than 5 Percent on Behalf of Another Person.**

Not Applicable

**Item 7. Identification and Classification of the Subsidiary**

See disclosure in Item 2 hereof.

**Item 8. Identification and Classification of Members of the Group**

Not Applicable

**Item 9. Notice of Dissolution of Group**

Not Applicable

**Item 10. Certification:**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**venBio Global Strategic Fund IV, L.P.**

**Date:** 11/17/2025

**By:** /s/ David Pezeshki

**Name & Title:** David Pezeshki, as attorney-in-fact for Corey Goodman and Robert Adelman, Members of the General Partner

**venBio Global Strategic GP IV, LLC**

**Date:** 11/17/2025

**By:** /s/ David Pezeshki

**Name & Title:** David Pezeshki, as attorney-in-fact for Corey Goodman and Robert Adelman, Members

**Adelman Robert J**

**Date:** 11/17/2025

**By:** /s/ David Pezeshki

**Name & Title:** David Pezeshki, as attorney-in-fact

**GOODMAN COREY S**

**Date:** 11/17/2025

**By:** /s/ David Pezeshki

**Name & Title:** David Pezeshki, as attorney-in-fact